Sergey Semochkin

Xin Yu 2 collaborations

Stéphane de Botton 1 collaboration

Pau Montesinos 1 collaboration

Andre C Schuh 1 collaboration

Cristina Papayannidis 1 collaboration

Paresh Vyas 1 collaboration

Andrew H Wei 1 collaboration

Hans Ommen 1 collaboration

Hee-Je Kim 1 collaboration

Richard A Larson 1 collaboration

Jaime Koprivnikar 1 collaboration

Olga Frankfurt 1 collaboration

Felicitas Thol 1 collaboration

Jörg Chromik 1 collaboration

Jenny Byrne 1 collaboration

Arnaud Pigneux 1 collaboration

Xavier Thomas 1 collaboration

Olga Salamero 1 collaboration

Maria Belen Vidriales 1 collaboration

Vadim Doronin 1 collaboration

Hartmut Döhner 1 collaboration

Amir T Fathi 1 collaboration

Eric Laille 1 collaboration

Maroof Hasan 1 collaboration

Patricia Martin-Regueira 1 collaboration

Courtney D DiNardo 1 collaboration

Paul G Richardson 1 collaboration

Albert Oriol 1 collaboration

Meral Beksac 1 collaboration

Anna Marina Liberati 1 collaboration

Monica Galli 1 collaboration

Fredrik Schjesvold 1 collaboration

Jindriska Lindsay 1 collaboration

Katja Weisel 1 collaboration

Darrell White 1 collaboration

Thierry Facon 1 collaboration

Jesus San Miguel 1 collaboration

Kazutaka Sunami 1 collaboration

Peter O'Gorman 1 collaboration

Pieter Sonneveld 1 collaboration

Pawel Robak 1 collaboration

Steve Schey 1 collaboration

Thomas Doerr 1 collaboration

Amine Bensmaine 1 collaboration

Tsvetan Biyukov 1 collaboration

Teresa Peluso 1 collaboration

Mohamed Zaki 1 collaboration

Kenneth Anderson 1 collaboration

Meletios Dimopoulos 1 collaboration

None None 1 collaboration

Affiliations

Publications (2)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.

Réseau de co-auteurs